https://sti571inhibitor.com/ef....ficacy-as-well-as-sa
All patients with NSCLC and high PD-L1, treated with first-line pembrolizumab had been included. We collected medical information from client files, pathology and laboratory reports. Patient qualities, comorbidities, PS, and tumour faculties had been reported. Overall survival (OS), progression-free survival (PFS) and reaction rate (RR) had been calculated.Results 302 patients were included, 246 with PS 0-1, 56 with PS 2. RR was 72% among customers with PS 0-1 when compared with 45% w
Like
Comment
Share
